Role of Positron Emission Tomography as a Biologic Marker in the Diagnosis of Primary Progressive Aphasia: Two Case Reports
10.1007/s13139-018-0538-5
- Author:
Young Jin JEONG
1
;
Kyung Won PARK
;
Do Young KANG
Author Information
1. Department of Nuclear Medicine, Dong-A University College of Medicine and Medical Center, Dong-A University Hospital, 1, 3ga, Dongdaesin-dong, Seo-gu, Busan 602-715, Republic of Korea. dykang@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Primary progressive aphasia;
Positron emission tomography;
Fluorodeoxyglucose;
Amyloid;
Dopamine transporter;
Biomarker
- MeSH:
Amyloid;
Aphasia;
Aphasia, Primary Progressive;
Biomarkers;
Classification;
Diagnosis;
Dopamine;
Dopamine Plasma Membrane Transport Proteins;
Electrons;
Neurodegenerative Diseases;
Neuropathology;
Positron-Emission Tomography
- From:Nuclear Medicine and Molecular Imaging
2018;52(5):384-388
- CountryRepublic of Korea
- Language:English
-
Abstract:
Primary progressive aphasia (PPA) is a heterogenous neurodegenerative disorder characterized by declining language and speech ability. Various underlying neuropathologies can induce PPA, and the disorder is divided into three subtypes—progressive non-fluent aphasia, semantic variant aphasia, and logopenic aphasia—according to clinical features. Accurate disease classification and prediction of underlying diseases are necessary for appropriate treatment, but proper use of imaging tests is important because clinical information alone often makes it difficult to make accurate decisions. Because there is a characteristic metabolic pattern according to the subtypes, F-18 fluorodeoxyglucose positron emission tomography (PET) can indicate subtype classification. In addition, PETstudies for imaging amyloid or dopamine transporters play an important role in demonstrating underlying disease. The present case showed that PET imaging studies are useful in diagnosis and could be used as a biomarker in PPA.
